Vitiligo induced by dupilumab treatment: A case series
J Eur Acad Dermatol Venereol
.
2023 Nov;37(11):2259-2261.
doi: 10.1111/jdv.19132.
Epub 2023 May 10.
Authors
Hongyi Ren
1
,
Andressa L Akabane
2
,
Kiera Kelleher
3
,
Caroline Halverstam
4
,
Maria Hicks
5
,
Jordana R Schachter
6
,
Robert Silverman
7
,
Samuel Chachkin
8
,
Shany Sherman-Bergman
2
9
,
John E Harris
2
,
Victoria Kuohung
10
Affiliations
1
Virginia Commonwealth University School of Medicine, Richmond, Virginia, USA.
2
Department of Dermatology, UMass Chan Medical School, Worcester, Massachusetts, USA.
3
Pennsylvania Dermatology Group, Huntingdon Valley, Pennsylvania, USA.
4
Division of Dermatology, Department of Medicine, Albert Einstein College of Medicine, New York, New York, USA.
5
ForCare Medical Group, Tampa, Florida, USA.
6
Division of Dermatology, Department of Medicine, McGill University, Montreal, Quebec, Canada.
7
Department of Pediatrics, Medstar Georgetown University Hospital, Washington, District of Columbia, USA.
8
Abington Memorial Hospital, Abington, Pennsylvania, USA.
9
Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
10
DermCare Experts, Quincy, Massachusetts, USA.
PMID:
37114348
DOI:
10.1111/jdv.19132
No abstract available
Publication types
Letter
MeSH terms
Antibodies, Monoclonal, Humanized / adverse effects
Humans
Hypopigmentation*
Vitiligo* / chemically induced
Substances
dupilumab
Antibodies, Monoclonal, Humanized